{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:14:29Z","timestamp":1784178869030,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003463","name":"Haematology Society of Australia and New Zealand","doi-asserted-by":"publisher","award":["Clinical Fellowship Grant"],"award-info":[{"award-number":["Clinical Fellowship Grant"]}],"id":[{"id":"10.13039\/501100003463","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-52503-2","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T13:03:44Z","timestamp":1727442224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-2215","authenticated-orcid":false,"given":"S.","family":"Fiorenza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8806-2761","authenticated-orcid":false,"given":"Y.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Purushe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3744-0466","authenticated-orcid":false,"given":"T. J.","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5244-7865","authenticated-orcid":false,"given":"J.","family":"Sarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1079-9525","authenticated-orcid":false,"given":"D. H.","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Sheih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1885-1773","authenticated-orcid":false,"given":"E. L.","family":"Kimble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Kirchmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. D.","family":"Phi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5769-8409","authenticated-orcid":false,"given":"J.","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-3882","authenticated-orcid":false,"given":"A. V.","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Riddell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-4816","authenticated-orcid":false,"given":"Q.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3867-0232","authenticated-orcid":false,"given":"R.","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. G.","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-2603","authenticated-orcid":false,"given":"J. Y. H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-8685","authenticated-orcid":false,"given":"S.","family":"Henikoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. J.","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"52503_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nri.2017.146","volume":"18","author":"AN Henning","year":"2018","unstructured":"Henning, A. N., Roychoudhuri, R. & Restifo, N. P. Epigenetic control of CD8(+) T cell differentiation. Nat. Rev. Immunol. 18, 340\u2013356 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"52503_CR2","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1182\/blood.2019002936","volume":"135","author":"J Gauthier","year":"2020","unstructured":"Gauthier, J. et al. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. Blood 135, 1650\u20131660 (2020).","journal-title":"Blood"},{"key":"52503_CR3","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","volume":"11","author":"GM Chen","year":"2021","unstructured":"Chen, G. M. et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 11, 2186\u20132199 (2021).","journal-title":"Cancer Discov."},{"key":"52503_CR4","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"52503_CR5","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer, D. et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30, 492\u2013500 (2016).","journal-title":"Leukemia"},{"key":"52503_CR6","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1016\/j.celrep.2017.11.097","volume":"21","author":"BE Russ","year":"2017","unstructured":"Russ, B. E. et al. Regulation of H3K4me3 at Transcriptional enhancers characterizes acquisition of virus-specific CD8(+) T cell-lineage-specific function. Cell Rep. 21, 3624\u20133636 (2017).","journal-title":"Cell Rep."},{"key":"52503_CR7","doi-asserted-by":"publisher","unstructured":"Sheerin, D., O\u2019Connor, D., Pollard, A.J. & Mohorianu I. Effects of technical noise on bulk RNA-seq differential gene expression inference. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/843789 (2019).","DOI":"10.1101\/843789"},{"key":"52503_CR8","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med 28, 1848\u20131859 (2022).","journal-title":"Nat. Med"},{"key":"52503_CR9","doi-asserted-by":"publisher","unstructured":"Vallejo, A. F. et al. snPATHO-seq: unlocking the FFPE archives for single nucleus RNA profiling. Preprint at bioRxiv, https:\/\/doi.org\/10.1101\/2022.08.23.505054 (2022).","DOI":"10.1101\/2022.08.23.505054"},{"key":"52503_CR10","doi-asserted-by":"publisher","first-page":"eaaw3381","DOI":"10.1126\/science.aaw3381","volume":"367","author":"C Weinreb","year":"2020","unstructured":"Weinreb, C., Rodriguez-Fraticelli, A., Camargo, F. D. & Klein, A. M. Lineage tracing on transcriptional landscapes links state to fate during differentiation. Science 367, eaaw3381 (2020).","journal-title":"Science"},{"key":"52503_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13880-1","volume":"11","author":"A Sheih","year":"2020","unstructured":"Sheih, A. et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat. Commun. 11, 219 (2020).","journal-title":"Nat. Commun."},{"key":"52503_CR12","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41590-020-0747-9","volume":"21","author":"J Roels","year":"2020","unstructured":"Roels, J. et al. Distinct and temporary-restricted epigenetic mechanisms regulate human alphabeta and gammadelta T cell development. Nat. Immunol. 21, 1280\u20131292 (2020).","journal-title":"Nat. Immunol."},{"key":"52503_CR13","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41588-021-00941-9","volume":"53","author":"DH Janssens","year":"2021","unstructured":"Janssens, D. H. et al. Automated CUT&Tag profiling of chromatin heterogeneity in mixed-lineage leukemia. Nat. Genet. 53, 1586\u20131596 (2021).","journal-title":"Nat. Genet"},{"key":"52503_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrg3788","volume":"15","author":"CA Meyer","year":"2014","unstructured":"Meyer, C. A. & Liu, X. S. Identifying and mitigating bias in next-generation sequencing methods for chromatin biology. Nat. Rev. Genet. 15, 709\u2013721 (2014).","journal-title":"Nat. Rev. Genet."},{"key":"52503_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s42003-023-04747-9","volume":"6","author":"JR Rose","year":"2023","unstructured":"Rose, J. R. et al. Distinct transcriptomic and epigenomic modalities underpin human memory T cell subsets and their activation potential. Commun. Biol. 6, 363 (2023).","journal-title":"Commun. Biol."},{"key":"52503_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan, J. D. et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature 629, 201\u2013210 (2024).","journal-title":"Nature"},{"key":"52503_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan, A. E. et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature 629, 211\u2013218 (2024).","journal-title":"Nature"},{"key":"52503_CR18","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.4049\/jimmunol.1501896","volume":"196","author":"H Wei","year":"2016","unstructured":"Wei, H. et al. Cutting edge: Foxp1 controls naive CD8+ T cell quiescence by simultaneously repressing key pathways in cellular metabolism and cell cycle progression. J. Immunol. 196, 3537\u20133541 (2016).","journal-title":"J. Immunol."},{"key":"52503_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn7336","volume":"14","author":"IY Jung","year":"2022","unstructured":"Jung, I. Y. et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci. Transl. Med 14, eabn7336 (2022).","journal-title":"Sci. Transl. Med"},{"key":"52503_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature24633","volume":"552","author":"RS Akondy","year":"2017","unstructured":"Akondy, R. S. et al. Origin and differentiation of human memory CD8 T cells after vaccination. Nature 552, 362\u2013367 (2017).","journal-title":"Nature"},{"key":"52503_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.immuni.2022.02.004","volume":"55","author":"JR Giles","year":"2022","unstructured":"Giles, J. R. et al. Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers. Immunity 55, 557\u2013574.e557 (2022).","journal-title":"Immunity"},{"key":"52503_CR22","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.exphem.2016.06.002","volume":"44","author":"AS Wiekmeijer","year":"2016","unstructured":"Wiekmeijer, A. S. et al. Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms. Exp. Hematol. 44, 838\u2013849.e839 (2016).","journal-title":"Exp. Hematol."},{"key":"52503_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000445834","volume":"169","author":"Y Li","year":"2016","unstructured":"Li, Y., Wang, H., Lu, H. & Hua, S. Regulation of Memory T Cells by Interleukin-23. Int. Arch. Allergy Immunol. 169, 157\u2013162 (2016).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"52503_CR24","doi-asserted-by":"publisher","first-page":"e002840","DOI":"10.1136\/jitc-2021-002840","volume":"9","author":"R Qin","year":"2021","unstructured":"Qin, R. et al. Tryptophan potentiates CD8(+) T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. J. Immunother. Cancer 9, e002840 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"52503_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05489-7","volume":"9","author":"A Jain","year":"2018","unstructured":"Jain, A., Song, R., Wakeland, E. K. & Pasare, C. T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells. Nat. Commun. 9, 3185 (2018).","journal-title":"Nat. Commun."},{"key":"52503_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.996746","volume":"13","author":"Q Haas","year":"2022","unstructured":"Haas, Q. et al. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities. Front. Immunol. 13, 996746 (2022).","journal-title":"Front. Immunol."},{"key":"52503_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1615\/CritRevImmunol.v26.i3.10","volume":"26","author":"EA Rowell","year":"2006","unstructured":"Rowell, E. A. & Wells, A. D. The role of cyclin-dependent kinases in T-cell development, proliferation, and function. Crit. Rev. Immunol. 26, 189\u2013212 (2006).","journal-title":"Crit. Rev. Immunol."},{"key":"52503_CR28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.3389\/fimmu.2017.00802","volume":"8","author":"R Ruiz-Garc\u00eda","year":"2017","unstructured":"Ruiz-Garc\u00eda, R. et al. Acquired senescent T-cell phenotype correlates with clinical severity in GATA binding protein 2-deficient patients. Front Immunol. 8, 802 (2017).","journal-title":"Front Immunol."},{"key":"52503_CR29","doi-asserted-by":"publisher","first-page":"165.132","DOI":"10.4049\/jimmunol.204.Supp.165.32","volume":"204","author":"C Lu","year":"2020","unstructured":"Lu, C. et al. NF-kB1 induces T cell dysfunction to promote colon tumorigenesis. J. Immunol. 204, 165.132 (2020).","journal-title":"J. Immunol."},{"key":"52503_CR30","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med 26, 1878\u20131887 (2020).","journal-title":"Nat. Med"},{"key":"52503_CR31","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson, M. J. et al. A novel autologous CAR-T THERapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov. 13, 1982\u20131997 (2023).","journal-title":"Cancer Discov."},{"key":"52503_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","volume":"5","author":"S Filosto","year":"2024","unstructured":"Filosto, S. et al. Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7). Blood Cancer Discov. 5, 21\u201333 (2024).","journal-title":"Blood Cancer Discov."},{"key":"52503_CR33","doi-asserted-by":"publisher","first-page":"e150807","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli, S. et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J. Clin. Invest 132, e150807 (2022).","journal-title":"J. Clin. Invest"},{"key":"52503_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26159-1","volume":"12","author":"Q Shan","year":"2021","unstructured":"Shan, Q. et al. Tcf1 and Lef1 provide constant supervision to mature CD8(+) T cell identity and function by organizing genomic architecture. Nat. Commun. 12, 5863 (2021).","journal-title":"Nat. Commun."},{"key":"52503_CR35","doi-asserted-by":"publisher","first-page":"e0188882","DOI":"10.1371\/journal.pone.0188882","volume":"12","author":"KM Ramonell","year":"2017","unstructured":"Ramonell, K. M. et al. CXCR4 blockade decreases CD4+ T cell exhaustion and improves survival in a murine model of polymicrobial sepsis. PLoS One 12, e0188882 (2017).","journal-title":"PLoS One"},{"key":"52503_CR36","doi-asserted-by":"publisher","unstructured":"Detsika, M. G. et al. Upregulation of CD55 complement regulator in distinct PBMC subpopulations of COVID-19 patients is associated with suppression of interferon responses. preprint available at bioRxiv. https:\/\/doi.org\/10.1101\/2022.10.07.510750 (2022).","DOI":"10.1101\/2022.10.07.510750"},{"key":"52503_CR37","volume":"3","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. Differential expression of inhibitory receptor NKG2A distinguishes disease-specific exhausted CD8(+) T cells. MedComm (2020) 3, e111 (2022).","journal-title":"MedComm (2020)"},{"key":"52503_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/blood-2021-153871","volume":"138","author":"R Maity","year":"2021","unstructured":"Maity, R. et al. A BCL2L1 armoured BCMA targeting CAR T cell to overcome exhaustion and enhance persistence in multiple myeloma. Blood 138, 327\u2013327 (2021).","journal-title":"Blood"},{"key":"52503_CR39","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.4049\/jimmunol.1102429","volume":"189","author":"S Krishna","year":"2012","unstructured":"Krishna, S. et al. Chronic activation of the kinase IKKbeta impairs T cell function and survival. J. Immunol. 189, 1209\u20131219 (2012).","journal-title":"J. Immunol."},{"key":"52503_CR40","doi-asserted-by":"publisher","first-page":"182.132","DOI":"10.4049\/jimmunol.208.Supp.182.32","volume":"208","author":"R Toumi","year":"2022","unstructured":"Toumi, R., Deo, R., Bhise, S., Sarkar, S. & Kalia, V. Exploring the role of c-Myc in defining the fate of exhausted CD8 T cells. J. Immunol. 208, 182.132\u2013182.132 (2022).","journal-title":"J. Immunol."},{"key":"52503_CR41","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1007\/s00262-019-02430-9","volume":"68","author":"TR McCaw","year":"2019","unstructured":"McCaw, T. R. et al. Histone deacetylase inhibition promotes intratumoral CD8(+) T-cell responses, sensitizing murine breast tumors to anti-PD1. Cancer Immunol. Immunother. 68, 2081\u20132094 (2019).","journal-title":"Cancer Immunol. Immunother."},{"key":"52503_CR42","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4049\/jimmunol.175.2.647","volume":"175","author":"D DeRyckere","year":"2005","unstructured":"DeRyckere, D. & DeGregori, J. E2F1 and E2F2 are differentially required for homeostasis-driven and antigen-induced T cell proliferation in vivo. J. Immunol. 175, 647\u2013655 (2005).","journal-title":"J. Immunol."},{"key":"52503_CR43","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/ijc.32781","volume":"146","author":"N Ryan","year":"2020","unstructured":"Ryan, N. et al. STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma. Int J. Cancer 146, 1717\u20131729 (2020).","journal-title":"Int J. Cancer"},{"key":"52503_CR44","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.4049\/jimmunol.1303422","volume":"193","author":"S Tanaka","year":"2014","unstructured":"Tanaka, S. et al. CCAAT\/enhancer-binding protein alpha negatively regulates IFN-gamma expression in T cells. J. Immunol. 193, 6152\u20136160 (2014).","journal-title":"J. Immunol."},{"key":"52503_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00275-y","volume":"9","author":"C Liang","year":"2021","unstructured":"Liang, C., Huang, S., Zhao, Y., Chen, S. & Li, Y. TOX as a potential target for immunotherapy in lymphocytic malignancies. Biomark. Res 9, 20 (2021).","journal-title":"Biomark. Res"},{"key":"52503_CR46","doi-asserted-by":"publisher","first-page":"e20221288","DOI":"10.1084\/jem.20221288","volume":"220","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. CTCF mediates CD8+ effector differentiation through dynamic redistribution and genomic reorganization. J. Exp. Med. 220, e20221288 (2023).","journal-title":"J. Exp. Med."},{"key":"52503_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep23533","volume":"6","author":"FC Hsu","year":"2016","unstructured":"Hsu, F. C. et al. An essential role for the transcription factor Runx1 in T cell maturation. Sci. Rep. 6, 23533 (2016).","journal-title":"Sci. Rep."},{"key":"52503_CR48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/ni.2570","volume":"14","author":"Y Kidani","year":"2013","unstructured":"Kidani, Y. et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat. Immunol. 14, 489\u2013499 (2013).","journal-title":"Nat. Immunol."},{"key":"52503_CR49","doi-asserted-by":"publisher","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","volume":"184","author":"CR Good","year":"2021","unstructured":"Good, C. R. et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 184, 6081\u20136100 e6026 (2021).","journal-title":"Cell"},{"key":"52503_CR50","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41375-021-01172-x","volume":"35","author":"MHS Awwad","year":"2021","unstructured":"Awwad, M. H. S. et al. Selective elimination of immunosuppressive T cells in patients with multiple myeloma. Leukemia 35, 2602\u20132615 (2021).","journal-title":"Leukemia"},{"key":"52503_CR51","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3724\/abbs.2022144","volume":"54","author":"Z Jia","year":"2022","unstructured":"Jia, Z. et al. KLF7 promotes preadipocyte proliferation via activation of the Akt signaling pathway by Cis-regulating CDKN3. Acta Biochim. Biophys. Sin. (Shanghai) 54, 1486\u20131496 (2022).","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"52503_CR52","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nmeth.3799","volume":"13","author":"D Marbach","year":"2016","unstructured":"Marbach, D. et al. Tissue-specific regulatory circuits reveal variable modular perturbations across complex diseases. Nat. Methods 13, 366\u2013370 (2016).","journal-title":"Nat. Methods"},{"key":"52503_CR53","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1158\/2159-8290.CD-21-1508","volume":"12","author":"TL Wilson","year":"2022","unstructured":"Wilson, T. L. et al. Common trajectories of highly effective CD19-Specific CAR T cells identified by endogenous T-cell receptor lineages. Cancer Discov. 12, 2098\u20132119 (2022).","journal-title":"Cancer Discov."},{"key":"52503_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110632","volume":"39","author":"R Toumi","year":"2022","unstructured":"Toumi, R. et al. Autocrine and paracrine IL-2 signals collaborate to regulate distinct phases of CD8 T cell memory. Cell Rep. 39, 110632 (2022).","journal-title":"Cell Rep."},{"key":"52503_CR55","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2009.05.006","volume":"30","author":"Y Araki","year":"2009","unstructured":"Araki, Y. et al. Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity 30, 912\u2013925 (2009).","journal-title":"Immunity"},{"key":"52503_CR56","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjh.19117","volume":"203","author":"E Galli","year":"2023","unstructured":"Galli, E. et al. The CD4\/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity. Br. J. Haematol. 203, 564\u2013570 (2023).","journal-title":"Br. J. Haematol."},{"key":"52503_CR57","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke, F. L. et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 4, 4898\u20134911 (2020).","journal-title":"Blood Adv."},{"key":"52503_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev-genom-120220-085159","volume":"22","author":"PB Talbert","year":"2021","unstructured":"Talbert, P. B. & Henikoff, S. The Yin and Yang of histone marks in transcription. Annu. Rev. Genomics Hum. Genet 22, 147\u2013170 (2021).","journal-title":"Annu. Rev. Genomics Hum. Genet"},{"key":"52503_CR59","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41587-022-01588-5","volume":"41","author":"T Stuart","year":"2023","unstructured":"Stuart, T. et al. Nanobody-tethered transposition enables multifactorial chromatin profiling at single-cell resolution. Nat. Biotechnol. 41, 806\u2013812 (2023).","journal-title":"Nat. Biotechnol."},{"key":"52503_CR60","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342\u20131356.e1316 (2017).","journal-title":"Cell"},{"key":"52503_CR61","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.ccell.2023.08.015","volume":"41","author":"X Li","year":"2023","unstructured":"Li, X. et al. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell 41, 1835\u20131837 (2023).","journal-title":"Cancer Cell"},{"key":"52503_CR62","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/ni.2590","volume":"14","author":"M Mingueneau","year":"2013","unstructured":"Mingueneau, M. et al. The transcriptional landscape of alphabeta T cell differentiation. Nat. Immunol. 14, 619\u2013632 (2013).","journal-title":"Nat. Immunol."},{"key":"52503_CR63","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.4049\/jimmunol.176.3.1439","volume":"176","author":"T Willinger","year":"2006","unstructured":"Willinger, T. et al. Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T Cell Factor-1) following antigen encounter in vitro and in vivo1. J. Immunol. 176, 1439\u20131446 (2006).","journal-title":"J. Immunol."},{"key":"52503_CR64","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1182\/blood-2002-11-3577","volume":"101","author":"J Geginat","year":"2003","unstructured":"Geginat, J., Lanzavecchia, A. & Sallusto, F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101, 4260\u20134266 (2003).","journal-title":"Blood"},{"key":"52503_CR65","first-page":"3153","volume":"141","author":"ME Selli","year":"2023","unstructured":"Selli, M. E. et al. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction. Blood 141, 3153\u20133165 (2023).","journal-title":"Blood"},{"key":"52503_CR66","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","volume":"34","author":"S Qiu","year":"2024","unstructured":"Qiu, S. et al. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization. Cell Res. 34, 386\u2013388 (2024).","journal-title":"Cell Res."},{"key":"52503_CR67","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood 137, 323\u2013335 (2021).","journal-title":"Blood"},{"key":"52503_CR68","doi-asserted-by":"crossref","unstructured":"Hirayama, A. V. et al. A novel polymer-conjugated Human IL-15 improves efficacy of CD19-targeted CAR-T cell immunotherapy. Blood Adv. 7, 2479\u20132493 (2023).","DOI":"10.1182\/bloodadvances.2022008697"},{"key":"52503_CR69","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"52503_CR70","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B (Methodol.) 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B (Methodol.)"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52503-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52503-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52503-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T13:07:48Z","timestamp":1727442468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-52503-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["52503"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-52503-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.F. has filed and received license fees on patents for optimising CAR T cell function, has received research laboratory grants from Bristol Myers Squibb, and has consulted ad hoc for Prescient Therapeutics. E.L.K. receives research support from Juno Therapeutics, a BMS company. A.S.S. is a current employee of Umoja Biopharma. A.V.H. has received research funding from Juno Therapeutics, a Bristol Myers Squibb Company, and Nektar Therapeutics; it has received honoraria from Bristol Myers Squibb. J.G. reports honoraria from EUSA Pharma, JMP, Larvol, and Multerra Bio; serves on scientific advisory boards for Legend Biotech, Janssen, Kite (a Gilead company), and MorphoSys; and receives research funding from Sobi, Juno Therapeutics, Celgene (a BMS company), and Angiocrine Bioscience. S.R.R. is a cofounder and adviser to Lyell Immunopharma; has research funding from and intellectual property licensed to Lyell Immunopharma; was a cofounder of Juno Therapeutics; is an inventor of patents licensed to Juno Therapeutics; and served as an adviser to Juno Therapeutics and Adaptive Biotechnologies. D.G.M. has received research funding from Juno Therapeutics, a Bristol Myers Squibb Company, Celgene, and Kite Pharma, a Gilead company; has served on ad hoc advisory board meetings from Amgen, BMS, Genentech, Gilead, Incyte, Janssen, Legend Biotech, Mustang Bio, MorphoSys, Novartis, Pharmacyclics, and Umoja; has rights to receive royalties from Fred Hutch for patents licensed to Juno Therapeutics; serves on scientific advisory board with stock options and compensations for A2 Biotherapeutics and Navan Technologies. S.H. has filed patent applications on related work. C.J.T. received research funding from Juno Therapeutics\/BMS, Nektar Therapeutics, and Nanostring; serves on Scientific Advisory Boards for Caribou Biosciences, T-CURX, Myeloid Therapeutics, ArsenalBio, Cargo Therapeutics, Celgene\/BMS Cell Therapy, Differentia Bio, eGlint, and Advesya; is a DSMB member for Kyverna; has served on ad hoc advisory roles\/consulting (last 12 months) for Prescient Therapeutics, Century Therapeutics, IGM Biosciences, Abbvie, Boxer Capital, Novartis; holds stock options for Eureka Therapeutics, Caribou Biosciences, Myeloid Therapeutics, ArsenalBio, Cargo Therapeutics, and eGlint; and has the right to receive payment from Fred Hutch Cancer Center as an inventor on patents related to CAR T-cell therapy. The remaining authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8309"}}